101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Mark Guerin Departs as CFO; Maria Maccecchini Named Acting CFO
Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
Webinar January 28, 2026 Presenter: Maria Maccecchini, Ph.D., President and CEO
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence